Skip to main content

AstraZeneca strikes $1 billion deal for Pfizer rare-disease gene therapies

Stock gains 5% after AstraZeneca's second-quarter results top analyst expectations.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.